Scarica l'app Stockscreener
39.89
1.77%
-0.72
Dopo l'orario di chiusura:
39.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Can Castle Biosciences Inc. stock continue upward trendWeekly Profit Analysis & Daily Profit Maximizing Tips - ulpravda.ru
What risks investors should watch in Castle Biosciences Inc. stock2025 Support & Resistance & AI Powered Buy/Sell Recommendations - ulpravda.ru
Is Castle Biosciences Inc. stock near bottom after declineRisk Management & Reliable Breakout Forecasts - ulpravda.ru
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 1,339 Shares of Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 2,678 Shares of Stock - MarketBeat
Castle Biosciences Inc (FRA:086) Stock Price, Trades & News - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What drives Castle Biosciences Inc stock priceWeekly Market Snapshot & Affordable Trading Plans - earlytimes.in
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline - MSN
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 830 Shares - MarketBeat
Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus - Yahoo Finance
Is Castle Biosciences Inc. stock vulnerable to regulatory risksHealthcare Stock Analysis & Free Professional Investment Consultations - bollywoodhelpline.com
Breakouts Watch: Why Castle Biosciences Inc. stock is considered a top pick2025 Sector Review & Real-Time Volume Triggers - moha.gov.vn
What makes Castle Biosciences (CSTL) a good fit for 'trend investing' - MSN
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' - sharewise.com
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt? - 富途牛牛
Castle Biosciences stock hits 52-week high at 40.66 USD - Investing.com
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High After Analyst Upgrade - MarketBeat
Castle Biosciences stock hits 52-week high at 40.66 USD By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Receives Analyst Rating Update with Ra - GuruFocus
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at Canaccord Genuity Group - MarketBeat
Is Castle Biosciences Inc. stock a top momentum playWeekly Investment Recap & Safe Swing Trade Setup Alerts - Улправда
Why Castle Biosciences Inc. stock is favored by top institutionsJuly 2025 Chart Watch & Smart Investment Allocation Tips - Улправда
Is Castle Biosciences Inc. stock positioned for digital transformationJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - Улправда
Castle Biosciences (NASDAQ:CSTL) Insider Sells $20,380.36 in Stock - MarketBeat
Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 14,888 Shares - MarketBeat
Why retail investors favor Castle Biosciences Inc. stockPortfolio Value Summary & Fast Momentum Entry Tips - Улправда
Castle Biosciences (CSTL) Awards Restricted Stock Units to New E - GuruFocus
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Castle Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule - TradingView — Track All Markets
Can Castle Biosciences Inc. stock maintain operating marginsTrade Entry Report & Fast Exit and Entry Trade Guides - Улправда
Is Castle Biosciences Inc. stock a buy before product launchesMarket Trend Review & Real-Time Volume Analysis - Улправда
Is Castle Biosciences Inc. stock trading at a premium valuationJuly 2025 Price Swings & Long-Term Safe Return Strategies - Улправда
Squarepoint Ops LLC Buys 28,359 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
COO Oelschlager Files To Sell 14,888 Of Castle Biosciences Inc [CSTL] - TradingView — Track All Markets
Castle Biosciences (CSTL) CEO reports stock sales under 10b5-1 plan - Stock Titan
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Reveals Enhanced Predictive Method for Uveal Melanoma Outcomes - GuruFocus
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study - Investing.com
Castle Biosciences Announces Key Study Findings on Uveal Melanoma Risk Stratification Using DecisionDx-UM and PRAME Combination - Quiver Quantitative
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma - GlobeNewswire
CFO Stokes Sells 4,496 ($168.4K) Of Castle Biosciences Inc [CSTL] - TradingView — Track All Markets
Castle Biosciences (CSTL) CCO reports sale of 13,200 shares - Stock Titan
Castle Biosciences (CSTL) CFO reports 4,496-share insider stock sale - Stock Titan
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test - Yahoo Finance
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at BTIG Research - MarketBeat
0.37%
2.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):